When prescribing inhalers the drug, device (e.g. MDI, Easibreathe, Autohaler, Accuhaler), strength (micrograms per inhalation), number of puffs per dose and frequency MUST be specified
In patients with COPD it is now recommended that long acting muscarinic antagonist SHOULD only be prescribed with a long-acting beta2 agonists (if no asthmatic features) REF NICE NG 115, GOLD 2023
Ipratropium |
Formulary
|
Nebuliser solution 250micrograms/1mL, 500micrograms/2mL |
|
Glycopyrronium Seebri breezhaler® |
Formulary
|
Hard capsule 44 micrograms per inhalation with Seebri Breezhaler® device |
|
Tiotropium |
Formulary
|
COPD Spiriva 18 microgram inhalation powder, hard capsule, Spiriva Respimat 2.5 microgram, inhalation solution, Tiotropium (Braltus) 10mcg Inhalation Powder Prescribe by brand |
MHRA: Braltus (tiotropium): risk of inhalation of capsule if placed in the mouthpiece of the inhaler MHRA: Tiotropium delivered via Respimat compared with Handihaler: no significant difference in mortality in TIOSPIR trial |
|
Tiotropium |
Formulary
|
Asthma Spiriva Respimat 2.5 microgram, inhalation solution Only Respimat® device is licensed for asthma |
MHRA Drug Safety Update May 2018: Braltus (tiotropium): risk of inhalation of capsule if placed in the mouthpiece of the inhaler |
|